Welcome to our dedicated page for Xeris Biopharma Holdings news (Ticker: XERS), a resource for investors and traders seeking the latest updates and insights on Xeris Biopharma Holdings stock.
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) is a biopharmaceutical company headquartered in Chicago, Illinois, with a commercial portfolio and pipeline focused on endocrine and neurological conditions. News about Xeris frequently centers on the performance of its three marketed products—Recorlev, Gvoke, and Keveyis—as well as updates on its lead pipeline candidate, XP-8121, and its proprietary XeriSol and XeriJect formulation platforms.
Investors following XERS news can expect regular coverage of quarterly and full-year financial results, including product-level revenue for Recorlev, Gvoke, and Keveyis, trends in patient demand, and commentary on profitability metrics such as Adjusted EBITDA. The company’s press releases and accompanying Form 8-K filings provide detailed breakdowns of revenue, costs, and operating performance, along with management’s discussion of strategic priorities.
Xeris news flow also includes announcements related to intellectual property, such as Orange Book listings and patent notices for Recorlev and XP-8121, as well as partnership updates like the agreement with American Regent for the commercialization of Gvoke VialDx in the United States. Additional items may cover analyst and investor events, revenue guidance updates, and long-term outlooks that management shares with the market.
For those tracking developments in Xeris’ pipeline, news items highlight regulatory milestones, patent allowances, and R&D investment in XP-8121 and other early-stage programs using XeriSol and XeriJect. By monitoring this news page, readers can review a chronological record of Xeris’ operational, financial, and strategic announcements as they are released.
Xeris Biopharma Holdings (Nasdaq: XERS) announced that its commercialization partner, Tetris Pharma, will be acquired by Arecor Therapeutics, contingent upon Arecor's successful capital offering. Upon completion, Arecor is set to continue the commercialization of Ogluo in the UK and EEA. The acquisition aims to leverage Arecor's resources to enhance the marketing of Ogluo, a glucagon treatment for severe hypoglycemia in diabetes patients. Xeris will still be responsible for product supply and anticipates a smooth transition of commercial activities.
Xeris Biopharma Holdings (NASDAQ: XERS) presented new findings on Cushing's syndrome (CS) at the AACE Annual Meeting held from May 12-14, 2022. Key highlights include the LOGICS study, a phase 3 trial showing that patients on placebo had a significantly worse mean urinary-free cortisol (mUFC) response than those on Recorlev® (levoketoconazole). Additionally, a burden of illness study indicated that CS patients report moderate impairment in health-related quality of life, with 89% using over-the-counter analgesics for symptom relief. No new safety signals for Recorlev were identified during the study.
Xeris Biopharma Holdings reported Q1 2022 net product revenue of $21.9M, reflecting a 33% increase year-over-year on a pro forma basis. The company ended the quarter with $132.1M in cash and equivalents, affirming 2022 revenue guidance of $105M - $120M and aiming for cash flow breakeven by year-end 2023. Key products like Gvoke achieved over 30,000 prescriptions, a growth of 88%. However, net loss for the quarter stood at $33.7M, compared to $18.4M in Q1 2021.
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) will announce its first quarter 2022 financial results before the U.S. market opens on May 11, 2022. A conference call and webcast will follow at 8:30 a.m. ET for investors to discuss the results. Xeris specializes in unique therapies for endocrinology, neurology, and gastroenterology, with three available products: Gvoke®, Keveyis®, and Recorlev®. The company aims to expand its pipeline with novel treatments utilizing its proprietary formulation technologies.
Xeris Biopharma Holdings (Nasdaq: XERS) announced the availability of the Gvoke® Kit, a ready-to-use glucagon injection for severe hypoglycemia, now accessible by prescription. This kit includes a single-dose sterile syringe and vial, designed for those at risk of low blood sugar events. The Gvoke products received FDA approval in September 2019 and August 2021. The company, headquartered in Chicago, aims to meet the growing demand among patients to keep Gvoke readily available for emergencies.
Xeris Biopharma Holdings (XERS) completed the acquisition of Strongbridge Biopharma, realizing $50M in synergies by year-end 2022. Pro forma net product revenues rose to $79M in FY '21, a 56% increase. Expected growth for 2022 is $105M-$120M with cash resources projected at $90M-$110M by year-end. The company anticipates reaching cash flow breakeven by the end of 2023. Key product sales, including Gvoke and Recorlev, are driving growth, alongside a strong cash position bolstered by recent financing moves.
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) has secured a $150 million senior secured term loan from Hayfin Capital Management. The initial drawdown of $100 million will repay existing debts and enhance working capital. Xeris aims for cash flow breakeven by year-end 2023, leveraging a total capital base of approximately $180 million. The debt facility has a five-year maturity with a 9% interest rate and provides additional borrowing flexibility. Xeris' CFO noted this agreement increases financial strength while protecting shareholder interests through non-dilutive capital.
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) announces the release of its fourth quarter and full year 2021 financial results on March 10, 2022, prior to U.S. market open. A conference call and webcast will follow at 8:30 a.m. ET to discuss the results. The company specializes in developing therapies for endocrinology, neurology, and gastroenterology, with products like Gvoke® and Keveyis®. Xeris also has ongoing development programs supported by proprietary formulation technologies.
Xeris Biopharma (Nasdaq: XERS) announced that its CEO, Paul R. Edick, will participate in the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, at 12:00pm Eastern Time. The event will include a fireside chat format and will be accessible via a live webcast on the company's investor relations website. Xeris is focused on developing unique therapies in endocrinology, neurology, and gastroenterology, with products like Gvoke® for severe hypoglycemia and Recorlev® for Cushing’s syndrome, among others.
Xeris Biopharma Holdings (NASDAQ: XERS) announced that its drug Recorlev (levoketoconazole) is now exclusively available through PANTHERx Rare Specialty Pharmacy. This FDA-approved treatment for Cushing's syndrome enhances patient access through the Xeris CareConnection program, offering $0 co-pay for insured individuals and comprehensive support services. Recorlev aims to address the needs of patients unable to undergo surgery. It received positive Phase 3 study results, demonstrating significant efficacy in reducing cortisol levels.